Lucine is a health-focused startup that aims to revolutionize pain management with its innovative digital therapeutic device. Their slogan, "Empower your health journey with an innovative approach to pain relief, delivering rapid results through personalized neurostimulation," encapsulates their mission to provide fast-acting, personalized pain relief solutions. Founded in 2017, the company operates in the Big Data, Biotechnology, Health Care, Information Technology, and Pharmaceutical industries. Their latest milestone includes a €5.50M Seed Round investment on 18 November 2020, with key investors such as Bpifrance, Kurma Partners, BNP Paribas Developpement, AQUITI Gestion, and IRDI SORIDEC Gestion.
Lucine's unique approach involves leveraging active substances to facilitate analgesic neurostimulation for rapid pain relief, with the capability to alleviate pain within five minutes. What sets their solution apart is its customization, utilizing real-time measurement and analysis of pain through facial, vocal, and postural recognition to tailor the neurostimulation to individual needs. This tailored approach underlines their commitment to revolutionizing pain management and enhancing patient health.
